TriNetX acquires Belgium-based Custodix

TriNetX has just acquired Custodix, a Belgian-based provider of clinical trial patient recruitment solutions.

TriNetX is a global health research network that has revolutionised clinical research. Custodix is a provider of clinical trial patient recruitment solutions offering a range of solutions for ensuring compliance with European and US data protection legislation and security best practices. The InSite platform offered by Custodix is designed to enable secure and trustworthy reuse of EHR data. 

The acquisition of Custodix by TriNetX will bring new pharmaceutical-sponsored clinical trials to healthcare organisations across Europe. The InSite Network from Custodix is currently active in 12 countries throughout Europe. The acquisition makes sense as InSite will complement the existing TriNetX footprint in Europe. TriNetX also has an impressive network of healthcare organisations globally in the US, Japan, Singapore, Malaysia, Philippines, India, Israel, and Brazil. This acquisition is part of TriNetX's plans of international expansion and will result in establishing the largest research network in Europe and will give healthcare organisations greater access to clinical trial opportunities. 

TriNetX has a terrific customer base including 11 of the largest pharmaceutical companies including Novartis, Sanofi, Pfizer and top contract research organisations including Syneos and ICON. 

"This is a breathtaking unification of two extremely compatible research networks," said Gadi Lachman, TriNetX CEO. "The two companies launched in separate geographies, but share a commitment to strong compliance, governance, and a global vision for clinical research. We now offer the world’s largest platform for clinical research, providing a more powerful resource for pharma companies and healthcare organizations, and more hope for patients in need. This expansion gives us additional local leadership, regional support, and increased resources in the European market."

This acquisition will quadruple the size of TriNetX's European staff and will give it the foundation it needs to further expand in Europe and Asia. Custodix's CEO Brech Clearhout will be the new Managing Director of TriNetX's European Division which will be known as InSite. 

"This deal is exciting news for the healthcare organizations in our InSite network," said Brecht Claerhout. "We share similar values to TriNetX, which will enable us to continue collaborating with the hospital community, service our customer base as we always have, and bring new clinical trial opportunities to researchers and their patients."